BR112012019459A2 - identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. - Google Patents

identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.

Info

Publication number
BR112012019459A2
BR112012019459A2 BR112012019459A BR112012019459A BR112012019459A2 BR 112012019459 A2 BR112012019459 A2 BR 112012019459A2 BR 112012019459 A BR112012019459 A BR 112012019459A BR 112012019459 A BR112012019459 A BR 112012019459A BR 112012019459 A2 BR112012019459 A2 BR 112012019459A2
Authority
BR
Brazil
Prior art keywords
tor kinase
sensitivity
identification
kinase inhibitors
predictive biomarker
Prior art date
Application number
BR112012019459A
Other languages
English (en)
Portuguese (pt)
Inventor
Chopra Rajesh
Sankar Sabita
Xu Shuichan
Xu Weiming
Ning Yuhong
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44355759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012019459(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of BR112012019459A2 publication Critical patent/BR112012019459A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112012019459A 2010-02-03 2011-02-03 identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. BR112012019459A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30115010P 2010-02-03 2010-02-03
US36298210P 2010-07-09 2010-07-09
PCT/US2011/023524 WO2011097333A1 (en) 2010-02-03 2011-02-03 Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112012019459A2 true BR112012019459A2 (pt) 2017-10-17

Family

ID=44355759

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019459A BR112012019459A2 (pt) 2010-02-03 2011-02-03 identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.

Country Status (24)

Country Link
US (1) US9555033B2 (enExample)
EP (2) EP2531194B1 (enExample)
JP (1) JP6114554B2 (enExample)
KR (2) KR101942212B1 (enExample)
CN (1) CN102821767A (enExample)
AR (1) AR080643A1 (enExample)
AU (1) AU2011212927B2 (enExample)
BR (1) BR112012019459A2 (enExample)
CA (1) CA2788678C (enExample)
CR (1) CR20120406A (enExample)
EC (1) ECSP12012080A (enExample)
ES (1) ES2670659T3 (enExample)
HK (1) HK1221642A1 (enExample)
IL (1) IL221282A (enExample)
MX (1) MX2012009030A (enExample)
NI (1) NI201200128A (enExample)
NZ (1) NZ601581A (enExample)
PH (2) PH12012501581A1 (enExample)
RU (1) RU2565034C2 (enExample)
SG (1) SG183155A1 (enExample)
TW (1) TWI578989B (enExample)
UA (1) UA110697C2 (enExample)
WO (1) WO2011097333A1 (enExample)
ZA (1) ZA201305379B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2739751A1 (en) * 2011-08-03 2014-06-11 Signal Pharmaceuticals, LLC Identification of gene expression profile as a predictive biomarker for lkb1 status
SG10201912850WA (en) * 2011-10-19 2020-02-27 Signal Pharm Llc Treatment Of Cancer With TOR Kinase Inhibitors
ES2694413T3 (es) 2011-12-02 2018-12-20 Signal Pharmaceuticals, Llc Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
WO2013103836A2 (en) * 2012-01-05 2013-07-11 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
CA2864905A1 (en) * 2012-02-24 2013-08-29 Signal Pharmaceuticals, Llc Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
ES2944478T3 (es) 2013-04-17 2023-06-21 Signal Pharm Llc 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MX368286B (es) * 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
KR102242505B1 (ko) 2013-04-17 2021-04-20 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
KR101602532B1 (ko) 2013-08-29 2016-03-11 경북대학교 산학협력단 위암의 재발 가능성 예측을 위한 정보제공 방법
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
KR101765335B1 (ko) * 2014-09-26 2017-08-22 서울대학교산학협력단 암 세포 조영용 ｍｒｉ 조영제 조성물
KR101720046B1 (ko) * 2014-09-26 2017-03-29 서울대학교산학협력단 광역학 치료용 자기조립형 약학 조성물
JP6964343B2 (ja) 2015-11-20 2021-11-10 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
HUE054548T2 (hu) 2016-12-20 2021-09-28 Astrazeneca Ab Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
RU2646513C1 (ru) * 2017-08-30 2018-03-05 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного рака легкого iiв-iiiа стадии
CN109298102B (zh) * 2018-12-03 2021-09-21 瑞德肝脏疾病研究(上海)有限公司 一种药物肺部代谢特征的体外评价方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW274550B (enExample) * 1992-09-26 1996-04-21 Hoechst Ag
US6800436B1 (en) * 1997-11-27 2004-10-05 Chugai Seiyaku Kabushiki Kaisha Diagnostic method, diagnostic reagent and therapeutic preparation for diseases caused by variation in LKB1 gene
WO2000072670A1 (en) 1999-05-31 2000-12-07 Chugai Research Institute For Molecular Medicine, Inc. Lkb1 gene knockout animals
AR038703A1 (es) 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
PT2316831E (pt) 2002-11-21 2013-06-06 Novartis Ag 2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
ES2308198T3 (es) 2003-07-17 2008-12-01 University Of Dundee Metodos para el uso de un complejo lkb1/strad/mo25.
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
US20080194019A1 (en) * 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7608622B2 (en) * 2004-09-24 2009-10-27 Janssen Pharmaceutica Nv Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1828186A1 (en) * 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
MX2007010404A (es) 2005-02-25 2008-01-11 Kudos Pharm Ltd Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer.
KR20070113252A (ko) 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-디아미노-피리도피리미딘 유도체 및 이의 ｍＴＯＲ억제제로서의 용도
EP1940839B1 (en) 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
WO2007044729A2 (en) 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
JP5480503B2 (ja) 2005-10-07 2014-04-23 エクセリクシス， インク． ＰＩ３Ｋαのピリドピリミジノン型阻害剤
PT2385053E (pt) 2005-11-17 2013-12-17 Osi Pharm Inc Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
CA2628920C (en) 2005-11-22 2015-12-29 Kudos Pharmaceuticals Limited Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
WO2007080382A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
UA95799C2 (en) 2006-04-26 2011-09-12 Ф. Хоффманн-Ля Рош Аг Pharmaceutical compounds
CN101484438A (zh) 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 吡唑衍生物及其作为p13k抑制剂的用途
EP2016075A1 (en) 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
AU2007287430B2 (en) 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032027A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
US20090233926A1 (en) 2006-09-14 2009-09-17 Astrazeneca 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
CN101535296A (zh) 2006-09-14 2009-09-16 阿斯利康(瑞典)有限公司 作为p13k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-苯基嘧啶衍生物
WO2008032064A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032028A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
ES2383370T3 (es) * 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
EP2457913B1 (en) * 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
CN102993202A (zh) 2006-11-20 2013-03-27 诺瓦提斯公司 2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
CA2692720A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
BRPI0814818A2 (pt) 2007-07-09 2019-09-10 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
WO2009007749A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CA2692725A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Compound - 946
CN101883774A (zh) 2007-10-16 2010-11-10 惠氏有限责任公司 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
CN102014914A (zh) 2008-01-15 2011-04-13 惠氏有限责任公司 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
WO2009102986A1 (en) 2008-02-15 2009-08-20 Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2516441B1 (en) 2009-12-23 2015-01-21 Elan Pharmaceuticals Inc. Pteridinones as inhibitors of polo-like kinase
US20110318336A1 (en) * 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors

Also Published As

Publication number Publication date
KR101942212B1 (ko) 2019-01-24
NI201200128A (es) 2013-01-18
EP2992878A1 (en) 2016-03-09
KR20120123513A (ko) 2012-11-08
KR20170116201A (ko) 2017-10-18
CR20120406A (es) 2012-10-31
PH12012501581A1 (en) 2012-10-22
WO2011097333A1 (en) 2011-08-11
MX2012009030A (es) 2012-09-12
NZ601581A (en) 2014-03-28
CN102821767A (zh) 2012-12-12
US9555033B2 (en) 2017-01-31
AU2011212927A1 (en) 2012-08-23
RU2012137279A (ru) 2014-03-10
ZA201305379B (en) 2015-08-26
IL221282A (en) 2016-12-29
PH12020500203A1 (en) 2021-03-15
US20110257167A1 (en) 2011-10-20
HK1221642A1 (en) 2017-06-09
IL221282A0 (en) 2012-10-31
AU2011212927B2 (en) 2014-10-09
ES2670659T3 (es) 2018-05-31
AR080643A1 (es) 2012-04-25
ECSP12012080A (es) 2012-09-28
EP2531194B1 (en) 2018-04-18
CA2788678C (en) 2019-02-26
TWI578989B (zh) 2017-04-21
EP2531194A1 (en) 2012-12-12
JP2013518890A (ja) 2013-05-23
SG183155A1 (en) 2012-09-27
UA110697C2 (uk) 2016-02-10
EP2531194A4 (en) 2013-09-25
CA2788678A1 (en) 2011-08-11
JP6114554B2 (ja) 2017-04-12
TW201130846A (en) 2011-09-16
RU2565034C2 (ru) 2015-10-10

Similar Documents

Publication Publication Date Title
BR112012019459A2 (pt) identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
AR084831A1 (es) Terapia anticancer mediante inhibidores de quinasa
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
CU20120125A7 (es) Compuestos para la inhibición de inmunoproteasomas
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
MX2016007066A (es) Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112015012507A2 (pt) marcadores de diagnóstico para tratar distúrbios de proliferação celular com inibidores da telomerase
MX389168B (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
BR112015004653A2 (pt) método diagnóstico e terapêutico de câncer de moléculas alvo expressas em células-tronco cancerígenas
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
BR112013033836A2 (pt) terapia de combinação
BR112014004762A2 (pt) métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula
CR20140289A (es) Derivados de quinolina como inhibidores de la enzima pde10a
MX2013011184A (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
TN2013000368A1 (en) Glucosylceramide synthase inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2500 DE 04-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]